SANTA CLARA, Calif., March 10, 2020 /PRNewswire/ — Zeto, Inc., a privately held medical technology company that is transforming the Electroencephalography (EEG) experience for healthcare, today announced that it has raised $7.3 million in Series A financing led by Seraph Group and joined by Aphelion Capital, SV Tech Ventures and Shangbay Capital. Zeto raised $4 million previously in dilutive and non-dilutive funding. The new capital will be used to accelerate commercialization of its lead product, the zEEG headset and software platform, and develop new products to expand its portfolio. zEEG is the first true dry electrode EEG headset to be approved by the U.S. Food and Drug Administration (FDA) for clinical use.

“Since our commercial launch a few months ago, we added several customers who love the product and are utilizing it at high rates. We are glad to validate the strong product-market fit for zEEG. Inspired by the demand, we are excited to expand our commercial team and production capacity to serve our growing customer base,” said Aswin Gunasekar, MS, MBA, Chief Executive Officer and Founder of Zeto. “Our goal is to provide the most seamless and intelligent EEG experience for any clinical need. Current products are far behind what users need and Zeto is building a suite of convenient and intuitive products to eliminate the most time consuming and labor-intensive activities involved in traditional EEG. As a subsequent step, we plan to utilize artificial intelligence to not only supplement the reading physician with analytics and insight but also expand the diagnostic utility of EEG worldwide in areas of medicine where it has been underutilized.”

Zeto’s customer, Wave Neuroscience, Inc., said, “Our extensive intellectual property portfolio and business operations are built on award winning science and medical innovation. For us to achieve the high level of results we are committed to, we rely on partners that never rest in their quest to achieve the highest standards. Accessing an FDA compliant EEG device that performs at an uncompromising standard, allows for increased throughput and provides a user experience that rivals the latest technology assets, was very attractive to us. Zeto transformed the way we think about EEG capture by advancing technology further in the past two years than the industry had in the prior three or four decades. Zeto provides us the confidence, convenience and data quality that we rely on, day in and day out.”

“We believe a new era is around the corner when researchers can accelerate our understanding of the brain with this breakthrough device and software platform. It not only makes commercial sense, but also can serve as the infrastructure and library for neurological knowledge that leads to better diagnosis and treatment of brain disorders,” said Tuff Yen, CEO of Seraph Group, the lead investor.

“We are passionate about brainwaves, consider it a privilege to serve our customers and are committed to bringing great advancements for neurological care,” adds Aswin Gunasekar.

Source – https://www.prnewswire.com/news-releases/zeto-raises-series-a-funding-to-accelerate-commercialization-efforts-of-its-easy-use-electroencephalography-eeg-headset-and-software-platform-301020172.html

EEG is the gold standard for observing and characterizing neural activity, but patients are subject to lengthy and uncomfortable preparation for scans, and interpretation is subjective to the physician who reads it. Zeto has introduced a device designed for patient comfort and simple setup, which uses “active” dry electrodes capable of picking up cerebral activity with high digital resolution and less noise.

In Greek, the word zeto means “to live.” By that token, neural monitoring start-up Zeto Inc. was brought to life from the seed of a business school idea, with hopes of improving countless lives. Zeto’s CEO Aswin Gunasekar was in business school at the University of Texas, Austin, when he took an interest in epilepsy diagnosis after watching a family member battle the condition. Quickly realizing that the electroencephalogram (EEG), the gold standard for monitoring neural activity, has had few updates since its invention early in the 20^th century, innovation was an immediate priority for Gunasekar.

Current EEG systems are uncomfortable for patients, inefficient due to their lengthy setup, and variably interpretable in their output. Leveraging years of experience as an electrical engineer developing microprocessors, Gunasekar conceived of a business plan for an easy-to-use EEG testing alternative, which helped his MBA team win the venture creation class’ competition in 2013.

Gunasekar continued to develop it as he moved to Silicon Valley to work for PwC. During this period, his idea shifted from a patient-use home monitoring device to a professional, clinical, medical device. As it is today, the Zeto solution incorporates feedback from several hundred patients, neurologists, and EEG technologists to ensure its practicality in addressing the biggest pain points of those who use it most frequently.

Traditional EEG is used to observe seizures and diagnose epilepsy, sleep disorders, autism, stroke, concussion, and more. Testing involves the placement of 20 electrodes on the scalp, abrading the surface of the skin to lower impedance and using viscous gel to improve conductivity in order to boost the signal detected. The process requires a specially trained technologist and can take up to two hours to yield just 30 minutes’ worth of test results, the rest of the time lost to preparation, adjustment and clean up. The signal, once recorded, is highly intricate with many discrete elements that are challenging to translate into useful information.

Current EEG systems are inherently expensive to operate and maintain with such cost drivers as the time consumed, labor, equipment, consumables, maintaining the digital infrastructure to allow remote access for physicians as well as storage and archiving of patient recordings. Consequently, additional expenditure is incurred for IT personnel, third-party software, and data retrieval. According to Gunasekar, the broken EEG value chain has led to underutilization of EEGs in most US hospitals and unavailability in many rural, emergency, and international settings.

Finally, there is also a high degree of subjectivity between readers of EEG output. Signals are often manually annotated in various formats, with the data largely unstructured and not machine learnable.

“Today, the burden of obtaining a good signal is completely on the EEG technologist,” Gunasekar says. The placement of the sensors, as well as the mitigation of peripheral electrical activity that clouds the brain signal

with noise, requires training and experience to perfect. Precision placement is also a priority, as the goal is to capture neuronal activity at precise regions of the brain.

With Zeto’s device, a headset that resembles a bicycle helmet, much of the finessing required with traditional

EEG systems is eliminated. The sensors, designed for patient comfort, are mounted on a semi-rigid but adjustable frame, positionableto precise locations and calibrated to work dry (sans coupling gel), with no skin preparation, through all types of hair. In addition to EEG, Zeto’s patent pending hardware contains an added ECG sensor as well as video and auxiliary inputs for comprehensive monitoringcapability. Three clinical evaluations across 50 patients and the FDA clearance have so far validated that the device is at least

as effective as standard EEG systems with a more patient-friendly design and proprietary techniques for signal enhancement. The latter includes

Active Electrode Technology, which preamplifies and conditions the neural signal at the source, and Dynamic

Noise Cancellation, which detects and removes noise in real time, as audio headphones with a similar purpose do. Zeto’s revolutionary hardware connects to its intuitive cloud software that enables a secure, evolving AI engine with machine learning capability (currently in development), which will allow it to improve continuously through use as it gains experience. First, the data are standardized into a functional, searchable format, then are processed by the software to generate autonomous reports and assistance to give new insights to the attending doctor. By bringing to market arguably the most significant advancement to EEG technology since its inception, Gunasekar is aiming to not only disrupt the market, but lead it.

“We want to aid physicians tremendously with the EEG diagnostic for the future,” says Gunasekar. In line with this pursuit, Zeto is offering EEG interpretation services by board-certified neurologists to bridge any gap in knowledge when examining a particular scan. The combination of human expertise and tireless machine assistance will maximize the potential for meaningful analysis, overcoming the complexity and subtlety of neural signals. This new approach, for example, can guide attention to an area of the brain with particularly relevant activity, and search for similar patterns and connectedness to other regions across extended periods. That may lead to a more thorough understanding of neurological interaction and afflictions.

Zeto is introducing the first EEG headset backed by a cloud system to be cleared by the FDA for clinical use,

according to Gunasekar, who notes that the company is currently preparing for a CE mark. Zeto’s revenues will come from a capital equipment or subscription model, considering the pay-as-you-go nature for cloud connection and support. All of the company’s manufacturing is completed in-house, with production capacity capable of exceeding a few hundred units per month.

Gunasekar notes that both thought leaders and marketing partners will be engaged to help push Zeto to the forefront of the conversation among hospitals and clinics. The ease of its use allows for a demonstration that proves the product’s effectiveness in minutes, underscoring the intuitiveness of the headset, and serving as an instant visual representation of its increased efficiency and comfort over traditional EEG solutions.

With over 20 million clinical EEG procedures performed each year globally, Zeto’s initial target application of

short-term routine scans represents a $1.5 billion market, while follow-on products will address a $4 billion longterm EEG sector, and eventually a $10 billion future market that can positively impact autism, stroke, and concussion.

By Gunasekar’s assessment, Zeto’s 19-person close-knit team is its engine of innovation. “We have an incredibly passionate team that is locked in on transforming this space,” he says, “but we will really be smiling once our product has made this important medical test available to millions of people in

the world who need it.” The company is currently in an A round of financing, seeking $12 million, to fund its imminent commercial launch with an oversubscribed order pipeline for 2019.

Source – MedTech Strategist

Learn about ZETO and explore a whole new world of EEG.

Read case studies from Dr. Virginia Thornley and Joe Charles of JLC Services to learn more about our EEG headset’s applications. Visit our FAQ page for more on Zeto’s next gen EEG headset.

Zeto is a medical technology startup transforming the way EEG (Electroencephalography) is done at hospitals. They are solving a problem that has remained unsolved since EEG was invented in 1924, that is, an archaic, tedious approach that consumes time, requires a trained technician and puts the patient through a poor experience. This FDA approved wireless device is zero-prep, easy to wear headset with dry electrodes backed by a digital platform that offers instant upload, tools for analysis and remote interpretation by neurologists. Ena Sarkar meets the team and learns about this big disrupt in healthcare that opens new significant opportunities for conditions such as Epilepsy, Stroke, Concussion and Sleep disorders.

Read case studies from Dr. Virginia Thornley and Joe Charles of JLC Services to learn more about our EEG headset’s applications. Visit our FAQ page for more on Zeto’s next gen EEG headset.

Zeto EEG provides a better, more convenient EEG testing experience to patients and technicians and faster turnaround time to hospitals than current technology

SANTA CLARA, Calif., May 29, 2018 /PRNewswire/ — Zeto, Inc., a privately held medical technology company transforming the way electroencephalography (EEG) is done at hospitals, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its dry electrode EEG headset, called zEEG, for use in the clinical setting. The zEEG is the first FDA approved dry electrode EEG headset backed by a cloud platform that offers instant upload, tools for analysis and remote interpretation by neurologists.

“EEG is a critically important test for evaluation of patients with seizures or unexplained confusion that might be due to subtle seizures. Unfortunately, EEG technology has not evolved much since its inception almost 100 years ago, leaving EEG underutilized for neurological conditions,” said Robert S. Fisher, M.D., Ph.D., Director of the Stanford Epilepsy Center and former President of the American Epilepsy Society. “The zEEG technology will allow diagnosis and testing in hospitals and clinics that could not previously perform EEGs. This will be a very significant advance.”

“With the approval of zEEG, healthcare professionals and patients now have access to an EEG system that provides a simple, easy and convenient experience with the benefit of quick and smart analysis of data through our cloud platform,” said Aswin Gunasekar, MS, MBA, Chief Executive Officer and Founder of Zeto, Inc. “Our goal was to find a technology that would not only democratize access to EEG with a seamless platform but also unlock the potential of AI, opening up significant opportunities for conditions such as epilepsy, stroke, concussion and sleep disorders. We are proud to have developed a solution that presents a paradigm shift for EEG.”

A clinical study demonstrated that the zEEG headset provided EEG signal quality that was comparable to an approved, traditional EEG system. 30 patients in two study cohorts (EEG patients and healthy volunteers) were studied for specific time periods (up to 2 hours), and the zEEG was found to perform at least as well as the reference device based on predefined acceptance criteria. Study results will be published in the coming months.

“This approval is particularly meaningful to the Epilepsy Foundation, since the zEEG system was selected as the winner of the 2016 Epilepsy Foundation Shark Tank and was also awarded a New Therapy Commercialization Investment in 2017,” said Jacqueline French MD, Chief Scientific Officer of the Epilepsy Foundation and Professor of Neurology, NYU Langone Health’s Comprehensive Epilepsy Center. “We saw a great potential for the electroencephalogram, an old diagnostic technique, to take a great leap into the modern age, making it more accessible for diagnosis of epilepsy.”

The FDA approved the Zeto EEG system in April 2018. Zeto plans to continue working with leading hospital beta customers in preparation for a commercial launch later in the year.

About Zeto, Inc.

Zeto, Inc. is a privately held medical technology company located in Santa Clara, CA focused on transforming the way electroencephalography (EEG) is done at hospitals. Zeto’s revolutionary platform brings the traditional EEG procedure to the 21st century by offering zEEG, a zero-prep, wireless, easy-to-wear headset with 19 dry electrodes that can be positioned as per the 10-20 EEG system, backed by a cloud platform that offers instant upload, tools for analysis and remote interpretation by neurologists. The company plans to leverage its platform technology to improve access and affordability to brain wave testing and achieve better outcomes for neurological conditions such as epilepsy, stroke, concussion and sleep disorders, among others.

Source – https://www.prnewswire.com/news-releases/zeto-announces-first-dry-electrode-wireless-eeg-headset-approved-by-fda-for-clinical-use-300655286.html

Congratulations to Zeto and its CEO/Founder Aswin Gunasekar. The FDA has recently approved their product for clinical use. Zeto’s “dry electrode” headset, is the first of its kind to obtain FDA approval, enables doctors to obtain EEGs quickly and conveniently to 10-20 EEG specifications. The easy-use cloud platform makes EEG available to any health care facility.

Source – https://rosenmaninstitute.org/startup-news/2018/5/1/fda-approves-zetos-dry-electrode-headset-and-software-platform-for-eeg